UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapy TGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that…
Read More
A single-dose of Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour elimination in 83% of treated cases with no toxicity over 11 months and no tumour…
Read More
Trogenix's breakthrough Odysseus® platform targets cancer cells to deliver precision therapies with curative “one and done” potential across multiple aggressive, treatment-resistant cancers Financing round led…
Read More
Trogenix is proud to announce its recognition as Startup of the Year at the 2025 Innovation & Entrepreneurship Awards hosted by Cancer Research Horizons, the…
Read More
Atif Abbas, MD joins as CMO, bringing over 25 years’ experience in oncology drug development and clinical and regulatory strategy Carolyn Edwards, PhD appointed VP,…
Read More
Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
Accelerating Toward the Clinic in 2025 Trogenix has successfully achieved all milestones in platform and asset development, positioning the company to enter the clinic in…
Read More
Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
Trogenix recently hosted a landmark workshop at The Royal College of Surgeons in Edinburgh, uniting pioneering experts in neurosurgery, gene therapy, and oncology to advance…
Read More
Grant will accelerate development and evaluate Trogenix’s SSE technology in liver hepatocellular carcinoma and colorectal cancer liver metastases Edinburgh, UK, January 2024 - Trogenix Ltd…
Read More